Liñana Granell Carla, Belles Medall M Dolores, Ferrando Piqueres Raul, Montañes Pauls Belen, Álvarez Martín Tamara, Mendoza Aguilera Maria, Garcia Martinez Teresa
Department of Clinical Pharmacy, Hospital General Universitario de Castellón, Castellón de la Plana, Spain.
Eur J Hosp Pharm. 2019 Jan;26(1):16-22. doi: 10.1136/ejhpharm-2017-001222. Epub 2017 Aug 28.
To compare vancomycin dosage adjustment by evaluating trough concentrations (Ctrough) of vancomycin and its pharmacokinetic/pharmacodynamic (PK/PD) correlation (AUC/MIC ≥400).
A retrospective study of 52 adult haematological patients and 29 ICU patients was carried out. Dosage adjustment was performed in routine clinical practice with Ctrough and then compared using a PK/PD model. The probability of achieving the PK/PD target associated with the success of antimicrobial therapy was evaluated. When the susceptibility of the organism responsible for infection is not known, Monte Carlo simulation calculates the cumulative fraction of response (CFR) from the distribution of MIC values. Values of CFR >90% represent an optimal achieved regimen against a population of microorganisms.
According to dosage adjustment performed with Ctrough, in haematological patients the dose of vancomycin was increased in 65.4% compared with an increase in 53.8% of patients with the PK/PD model. No dose adjustment was needed in 21.1% of patients using Ctrough compared with 7.7% with the PK/PD model and in 13.5% of patients using Ctrough determination and in 38.5% of patients with the PK/PD model the dose was reduced. For ICU patients the dosage adjustment made with Ctrough resulted in an increased dose of vancomycin in 79.4% of patients compared with 41.4% with the PK/PD model. No dose adjustment was needed in 3.4% of patients using Ctrough in comparison with 13.8% with the PK/PD model, and the dose was reduced in 17.2% of patients using Ctrough determination and in 44.8% with the PK/PD model.
Data for bacterial susceptibility combined with measured data for antibiotic concentrations using a PK/PD model predict and improve the dosage adjustment for individual patients. A larger study with more complete datasets are needed for validation before it can be fully introduced into clinical practice.
通过评估万古霉素的谷浓度(Ctrough)及其药代动力学/药效学(PK/PD)相关性(AUC/MIC≥400)来比较万古霉素的剂量调整。
对52例成年血液学患者和29例ICU患者进行了回顾性研究。在常规临床实践中根据Ctrough进行剂量调整,然后使用PK/PD模型进行比较。评估实现与抗菌治疗成功相关的PK/PD目标的概率。当引起感染的病原体的敏感性未知时,蒙特卡洛模拟根据MIC值的分布计算累积反应分数(CFR)。CFR>90%的值代表针对微生物群体的最佳给药方案。
根据基于Ctrough进行的剂量调整,血液学患者中万古霉素剂量增加的比例为65.4%,而使用PK/PD模型的患者中这一比例为53.8%。使用Ctrough的患者中有21.1%不需要调整剂量,而使用PK/PD模型的患者中这一比例为7.7%;使用Ctrough测定的患者中有13.5%的剂量降低,而使用PK/PD模型的患者中有38.5%的剂量降低。对于ICU患者,根据Ctrough进行的剂量调整使79.4%的患者万古霉素剂量增加,而使用PK/PD模型的患者中这一比例为41.4%。使用Ctrough的患者中有3.4%不需要调整剂量,而使用PK/PD模型的患者中这一比例为13.8%;使用Ctrough测定的患者中有17.2%的剂量降低,而使用PK/PD模型的患者中有44.8%的剂量降低。
结合细菌敏感性数据和使用PK/PD模型测得的抗生素浓度数据可预测并改善个体患者的剂量调整。在完全引入临床实践之前,需要进行更大规模、数据集更完整的研究以进行验证。